Long-term survival following non-Hodgkin's lymphoma arising in Wiskott-Aldrich syndrome.
Wiskott-Aldrich syndrome (WAS) is a rare X-linked recessive trait, characterized by thrombocytopenia, eczema, immunodeficiency and a high risk of malignancy, usually leukaemia or lymphoma. Until recently, most patients died before the age of 10 years. A patient with WAS who developed extranodal non-Hodgkin's lymphoma at the age of 16 years is reported. Despite thrombocytopenia at presentation, chemotherapy was well tolerated. There was disease progression after first line chemotherapy and radiotherapy, but the patient responded to second line chemotherapy with cisplatin, vincristine and etoposide. He remains disease free 9 years after completing treatment.
Gilson
D
D
Yorkshire Centre for Clinical Oncology, Cookridge Hospital, Leeds, UK.
Taylor
R E
RE
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018450:Disease Progression; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000209:etiology* / Q000628:therapy; D008297:Male; D009918:Orbital Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000209:etiology* / Q000628:therapy; D018714:Radiotherapy, Adjuvant; D017741:Survivors; D014057:Tomography, X-Ray Computed; D014923:Wiskott-Aldrich Syndrome / Q000150:complications*